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Li-Fraumeni Syndrome (LFS) is a hereditary cancer syndrome which predisposes
individuals to cancer beginning in childhood. These risks are spread across a
lifetime, from early childhood to adulthood. Mutations in the p53 tumor suppressor
gene are known to cause the majority of cases of LFS. The risk for early onset
cancer in individuals with Li-Fraumeni Syndrome is high. Studies have shown that
individuals with LFS have a 90% lifetime cancer risk. Children under 18 have up to a
15% chance of cancer development. Effectiveness of cancer screening and
management in individuals with Li-Fraumeni Syndrome is unclear. Screening for
LFS-associated cancers has not been shown to reduce mortality. Due to the lack
of effective screening techniques for childhood cancers, institutions vary with
regard to their policies on testing children for LFS. There are currently no national
guidelines regarding predictive testing of children who are at risk of inheriting LFS.
No studies have looked at parental attitudes towards predictive p53 genetic
testing in their children. This was a cross-sectional pilot study aimed at describing
these attitudes. We identified individuals whose children were at risk for inheriting
p53 genetic mutations. These individuals were provided with surveys which
included validated measures addressing attitudes and beliefs towards genetic
testing. The questionnaire included qualitative and quantitative measures. Six
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individuals completed and returned the questionnaire with a response rate of
28.57%. In general, respondents agreed that parents should have the opportunity
to obtain p53 genetic testing for their child. Parents vary in regard to their attitudes
towards who should be involved in the decision making process and at what time
and under what considerations testing should occur. Testing motivations cited
most important by respondents included family history, planning for the future and
health management. Concern for insurance genetic discrimination was cited as
the most important “con” to genetic testing. Although limited by a poor response
rate, this study can give health care practitioners insight into testing attitudes and
beliefs of families considering pediatric genetic testing.
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Background
Li-Fraumeni Syndrome (LFS) is a hereditary cancer predisposition
syndrome which predisposes individuals to a large range of cancers beginning
in childhood. Individuals with LFS have up to a ninety percent lifetime risk of
developing cancer. Originally discovered through bedside clinical
observations and epidemiological studies, LFS has an estimated birth
prevalence of 1 in 5,000 (Lalloo, Varley, Ellis, O’Dair & Pharoah, 2003).
In the general population, cancer was the second leading cause of
death in 2006, preceded by heart disease (American Cancer Society, ACS,
2009). Men have a one in two lifetime cancer risk, while a woman’s lifetime
risk is one in three (ACS, 2009). These risks increase exponentially with age.
Most cancers occur sporadically throughout a person’s life-time, however,
five to ten percent of cancers can be attributed to a hereditary cause
(Schneider, 2002).
Greater than 200 hereditary cancer predisposition syndromes have
been identified (Schneider, 2002). As a group, hereditary cancer syndromes
confer an increased risk to individuals of developing certain cancer types in
their lifetime, often at younger ages than the general population. Individuals
with hereditary cancer syndromes often have a significant family history of
cancer with multiple generations and individuals affected with cancer.
Sometimes these individuals will have a personal or family history of a rare
cancer type such as male breast cancer, ovarian cancer or adrenocortical
carcinoma. It is crucial to recognize these syndromes in an individual as there
are established guidelines in regard to management, prevention and treatment
11

for most hereditary cancer syndromes. Once an individual has been identified
to have a hereditary cancer syndrome, it is important to notify other at risk
relatives and facilitate testing. It is often helpful for these individuals to meet
with a professional such as a physician or a genetic counselor to facilitate
education and testing (Schneider, 2002).
Established guidelines have been created regarding testing
individuals for several hereditary cancer syndromes. The main theme in these
guidelines is a risk/benefit analysis. In general, if the benefit of testing will
not manifest until adulthood, genetic testing is postponed until the age of 18
(American College of Medical Genetics (ACMG) & American Society of
Human Genetics (ASHG), 1995). Hereditary cancer syndromes, such as LiFraumeni syndrome, that confer a cancer risk in childhood but have no
established management, are more controversial. Testing for cancer
syndromes such as LFS is often at the discretion of the physician facilitating
the testing since there is currently a lack of guidelines regarding when to test
an individual for these conditions. It is also unclear what kind of management
should be implemented in hereditary cancer syndromes like LFS. The
American Society of Clinical Oncology (ASCO) recommends that physicians
and parents participate together in the decision making process (ASCO,
2003). Few studies have examined the interest parents have regarding having
their minor-aged child tested for a hereditary cancer syndrome in which
management in childhood is limited (Patenaude, Basili, Fairclough & Li,
1996). In 1969, Li and Fraumeni reported four families who appeared to have
autosomally dominant inherited cancers, including childhood cancers, soft
12

tissue sarcomas and breast cancer. This collection of cancers was termed LiFraumeni Syndrome, after the investigators who initially described it. In
1988, Li and Fraumeni searched the Cancer Family Registry of the National
Cancer Institute. They discovered twenty four individual families who had a
similar pattern of cancers. From this study, it became apparent that
individuals with Li-Fraumeni Syndrome had increased risks for brain tumors,
leukemia, breast cancer and adrenal cortical tumors. The researchers noted
that these cancers typically occurred before the age of 50 (Li et al., 1996).
Meanwhile, in 1978, Lynch observed several families with
apparent hereditary segregation of cancer which was consistent with LiFraumeni Syndrome. He too noted that these families had a predominance of
sarcoma, breast cancer, leukemia and adrenal cortical tumors. Lynch referred
to the collection of these specific cancers in one family as SBLA syndrome
(sarcoma, breast/brain, leukemia/laryngeal/lung cancer and adrenal cortical
carcinoma). A genetic segregation pattern was established for this hereditary
pattern of cancers which was compatible with autosomal dominant
inheritance. The study concluded that the reported kindred had a rare,
deleterious autosomal dominant aggregation of cancers (Lynch, Mulcahy,
Harris, Guirgis & Lynch, 1978). This mode of inheritance was then confirmed
by segregation analysis of 159 childhood soft tissue sarcoma patients in 1992
(Lustbader, Williams, Bondy, Strom & Strong, 1969).
The gene responsible for Li-Fraumeni Syndrome was discovered in
1990 (Malkin et al., 1990). Linkage analysis was not possible due to the rarity
of Li-Fraumeni Syndrome and its deleterious nature. Therefore, a candidate
13

gene approach was taken. Investigators were interested in p53 because of the
gene’s known involvement in the tumorigenesis of many sporadic cancers (it
is estimated that p53 is mutated in fifty percent of all sporadic tumors)
(Levine, 1997). In 1990, five families with LFS were analyzed. All of these
kindreds were found to have p53 mutations (Malkin et al., 1990). Soon,
another family which fit clinical criteria for LFS was tested. Several members
in this family tested positive for a mutation in p53 (Srivastave, Zou, Pirollo,
Blattner & Chang, 1990).
P53 is a tumor suppressor gene that is commonly mutated in
sporadic cancers. Termed “the guardian of the genome”, p53 is key in cell
cycle regulation (Lane, 1992). It has several functions including activation of
DNA repair, arresting the cell cycle and initiating apoptosis (Lane, 1992).
This explains why individuals with a germ line p53 mutation have a
significantly increased cancer risk. Tumor formation in individuals with p53
mutations is most often consistent with Knudson’s “two-hit” hypothesis, in
which cancer develops in individuals that inherit the “first hit” or mutation
and cancer occurs in cells that acquire a “second hit” or mutation (Levine,
1996)(Knudson, 1971). Therefore, it is important for individuals with a germ
line p53 mutation to avoid oncogenic environmental factors such as radiation.
Initially, it was thought that germ line mutations in another gene,
CHEK2, could account for other cases of LFS. Lee et al. (2001) and Varley
(2003) reported on several families with germ line CHEK2 mutations who
satisfied the LFS clinical criteria (Lee et al., 2001) (Varley,2003). Currently,
CHEK2 mutations are generally not considered a part of Li-Fraumeni
14

Syndrome. Rather, they are thought to be low penetrant tumor suppressor
genes involved in breast cancer (Vahteristo et al., 2002).
Li-Fraumeni Syndrome is an autosomal dominant and highly
penetrant hereditary cancer syndrome. Greater than seventy percent of
individuals with Li-Fraumeni Syndrome have a p53 germ line mutation
(Chompret, 2000). Mutations in the p53 tumor suppressor gene are known to
cause the majority of cases of LFS (Malkin, 1994). Commercial molecular
testing consists of direct sequencing of the p53 coding region, the first noncoding exon , promoter, all splice site junctions, and the 3’-untranslated
region, rearrangement and large duplication/deletion testing (Varley, 2003).
Unlike other cancer susceptibility syndromes, which may predispose
individuals to site-specific tumors, LFS increases an individual’s risk of
developing a variety of tumor types (Hartley, Birch, Kelsey, Marsden, Harris
and Teare, 1989) (Varley, 2003). The malignancies which dominate this
condition include soft tissue sarcoma, osteosarcoma, brain tumors, adrenal
cortical carcinoma and premenopausal breast cancer. Additional data suggests
that Li-Fraumeni Syndrome may also be associated with other diverse
neoplasms including pancreatic cancer, leukemia, Wilms’ tumor and
neuroblastoma(Li et al., 1988) (Birch et al., 2001) (Nichols, Malkin, Garber,
Fraumeni and Li, 2001). Other cancers have been seen in individuals with LiFraumeni Syndrome including renal, gonadal germ cell, melanoma, colon,
ovarian and lung cancer (Nichols et al., 2001) (Bougeard et al., 2008).
Individuals with LFS are clearly predisposed to tumor formation in a large
range of tissues and tissue types.
15

LFS increases an individual’s risk of developing multiple primary
tumors. These risks are spread across a lifetime, from early childhood to
adulthood, and the risk for early onset cancer in individuals with Li-Fraumeni
Syndrome is high. In 2000, Chompret et al. found that individuals with LiFraumeni Syndrome have a 15% chance of developing cancer from ages 0 to
15 and a 54% chance of developing cancer between ages 16 to 45 years.
Overall, the individuals in this study had up to a 68% lifetime risk of
developing cancer (Chompret et al., 2000). Bihan et al. (1995) studied five
individuals with p53 mutations and estimated age specific cancer risks. They
found that the risk for cancer was 42% in individuals aged 0 to 16, 38% in
individuals aged 17 to 45, and above 63% for individuals aged 45 and older.
Using segregation analysis, Lustbader et al. (1992) found that individuals
with Li-Fraumeni Syndrome had up to a 50% risk of cancer development by
age forty, and a 90% lifetime cancer risk (by age 60). By age thirty, nearly
50% of individuals with LFS will develop cancer, in comparison to only one
percent of the general population (Malkin et al., 1990). By age seventy, over
ninety percent of individuals with a germ line p53 mutation will develop a
malignancy (Malkin et al., 1990).
Cancer screening and management in individuals with Li-Fraumeni
Syndrome is not well defined. Screening for LFS-associated cancers,
however, has not been shown to reduce mortality (Varley, Evans & Birch,
1997). No proven beneficial methods for childhood cancers currently exist.
Methods that may be used to detect childhood cancers include blood cell
counts and radiographic studies, the predictive power of these tests is not
16

known. Magnetic resonance imaging (MRI) may be used to scan for
cancerous lesions. MRI is desirable because it can detect small lesions
without delivering radiation the body. This is important because individuals
with LFS are especially sensitive to radiation, which can potentiate tumor
development. Unfortunately, MRI is a costly procedure and may not be
available to all affected individuals (Varley et al., 1997).
Screening recommendations regarding LFS have been published
(National Comprehensive Cancer Network, NCCN, 2010) Screening for
children includes annual and thorough physicals,. Based on family history,
other forms of organ-targeted surveillance should be implemented. It is
important to keep in mind, however, that these screening methods have not
been proven to be effective. Screening for adults with LFS includes annual
physicals, dermatology evaluations. Women with LFS should have a clinical
breast exam biannually beginning at 20-25. They should rotate screening
methods between mammograms and breast MRI. All individuals with LiFraumeni Syndrome should consider colorectal cancer screening beginning at
age 20-25, with subsequent colonoscopies every two to five years. Again,
organ targeted surveillance should be practiced based on family history of
specific tumors (Varley, 1997) (Evans et al.,1997) (NCCN, 2010).
The use of MRI and PET (position emission tomography) scans in
screening for LFS-related tumors is controversial. Clinicians are inconsistent
in their attitudes towards the use of this technology in monitoring individuals
for cancer. Proponents of the method believe that it will detect lesions that are
otherwise undetectable. Others argue that it will subject the patient to many
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unnecessary biopsies and procedures (Wertz, Fanos & Reilly, 1994) (Varley
et al., 1997) (Goyen & Debatin, 2006).
Management and screening in individuals with LFS is a complicated
process since LFS is associated with a wide variety of tumors in several organ
systems. Several of the LFS associated cancers are difficult to detect until late
stages of its growth, and the later a cancer is detected, the poorer the
prognosis. Most importantly, individuals with LFS must be alert to changes in
their health and seek medical attention if they experience any symptoms
(Wertz, et al., 1994) (Varley, 2003) (Evans et al., 1997).
Due to the lack of appropriate screening techniques for childhood
cancers, institutions vary with regard to their policies on testing children for
Li-Fraumeni Syndrome. An international consortium of physicians and
researchers met in 1992 to develop a consensus towards management of and
testing individuals for LFS, and this meeting concluded that genetic testing
should not be offered to minors who are at risk of inheriting LFS. There has
been no follow-up in the last seventeen years to these recommendations (Li et
al., 1992)
Before the molecular cause of Li-Fraumeni Syndrome was
discovered, diagnosis was made on the basis of clinical criteria. Three criteria
guidelines exist for the diagnosis of Li-Fraumeni Syndrome.
A person who is diagnosed with LFS based on the classic or
original criteria must meet all three of the following:
1.

A proband with a sarcoma diagnosed before the age of 45
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2. A first degree relative with any cancer under the age of 45
3. A first or second degree relative with any cancer under the age
of 45 or a sarcoma at any age (Li & Fraumeni, 1969)
Following the creation of these criteria, a new set of guidelines was
set forth by Chompret et al. to diagnose individuals with LFS. These criteria
are less dependent on family history of cancer and focused more on an
individual’s personal history. An individual who has a clinical diagnosis of
LFS based on the Chompret criteria must meet one of the following:
1.

A proband with a tumor belonging to the LFS spectrum (soft
tissue sarcoma, osteosarcoma, brain tumor, premenopausal
breast cancer. Adrenal cortical carcinoma, leukemia, lung,
bronchoalveolar cancer) prior to the age of 46 years AND at
least one first or second degree relative with a LFS tumor
(excluding breast cancer if the proband has breast cancer)

2. A proband with multiple tumors (except multiple breast tumors).
Two of which belong to the LFS tumor spectrum and the first
tumor occurred before age 46
3. A proband with adrenocortical carcinoma or choroid plexus
tumor, irrespective of family history (Chompret, 2002)
Currently, Li-Fraumeni Syndrome is diagnosed in two ways:
clinically and molecularly. While historically individuals with Li-Fraumeni
syndrome were only given a clinical diagnosis, we now have the possibility to
perform genetic testing on individuals for molecular confirmation.
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Additionally, individuals who are at risk of inheriting LFS can have
predictive genetic testing based on the identified p53 mutation in the family.
Molecular testing of the p53 gene is now routinely performed to
facilitate the diagnostic process of LFS. Seventy percent of individuals who
fit the clinical description of LFS will have a mutation in the p53 gene, and
sequencing of the entire gene will detect ninety-five percent of p53 mutations
in these individuals (Birch et al., 1994) (Varley, 2003)(Bougeard et al., 2008).
The remaining five percent will have a deletion, rearrangement, or
unidentified mutation in the p53 gene (Nichols et al., 2001). Between 7 to
20% of p53 mutations are believed to be de novo events (Gonzalez et al.,
2009).
With new technology come new questions. Issues among debate in
the genetics community involve who should be tested for LFS and at what
age should testing occur (Li et al.,1992). When these questions are
considered, several things must be taken into account. What benefit would
genetic testing results have on the patient? At what age do cancer risks begin,
and are there affective approaches to manage these risks? These questions are
not specific to Li-Fraumeni syndrome and can be applied to all cancer
syndromes in general. Several agencies have set forth recommendations and
guidelines to help health professionals answer these difficult questions.
The American Society of Clinical Oncology (ASCO) published
recommendations regarding testing children for cancer susceptibility in
general. ASCO recommends that one should consider several variables when
deciding to offer testing to a potentially affected child. First, the child must
20

be at risk for a pediatric cancer. Also, the test under consideration should be
adequately interpretable, and the test results and implications should be clear
to the ordering clinician. Test results should be used for diagnosis, or
influence the medical management of the child, and evidence based risk
reduction strategies should be available (ASCO, 2003). Conditions such as
Multiple Endocrine Neoplasia (MEN) and Familial Adenomatous Polyposis
(FAP) have appropriate childhood interventions for their associated cancers
(Brandi et al., 2001) (Rozen and Macrael, 2006 ). Because of this, testing in
children at risk for these conditions is appropriate. Testing for the adult onset
cancer susceptibility syndromes such as Hereditary Breast and Ovarian
Cancer Syndrome (HBOC) and Lynch Syndrome (HNPCC) is typically not
recommended in minors since the benefit that individuals could derive from
these tests would not accrue until adulthood. ASCO enforces the belief that
the parents or guardian of the child should have the authority to decide
whether or not to test (ASCO, 2003).
The American Society of Human Genetics (ASHG) and the
American College of Medical Genetics (ACMG) published literature
regarding ethical, legal and psychosocial implications surrounding genetic
testing in minors (1995). In addition to emphasizing the necessity for a timely
medical benefit to the child, these guidelines focus on the need for genetic
testing to contribute to the global well-being of the child. Individuals
undergoing genetic testing may experience anxiety, altered self- image, and
uncertainty. ASHG and ACMG suggest that if the psychological or medical
benefits of testing won’t occur in childhood, testing should be postponed until
21

the child is old enough to make an autonomous competent decision. If the
balance of benefits and harms related to pediatric genetic testing is unclear,
ASHG and ACMG recommend that the provider respect the wishes and
decisions of the family, after adequate counseling. In the event that testing is
clearly harmful in the child, providers are encouraged to advocate for the best
interest of that child (ACMG/ASHG, 1995).
Upon reviewing national agency guidelines regarding predictive
testing in minors, one frequently encounters the concept of “best interest”.
For a genetic test to be justified, it must be in the best interest of the child,
both medically and psychologically. One key tenet in all genetic testing is
informed consent. Testing minors can be especially sensitive because a
minor’s informed consent cannot be given. Instead, it is up to the parent or
legal guardian to make medical decisions for the child. It is expected that
parents know their children better than health care providers and are therefore
in the unique position to determine what is in the best interest of their child
(Wertz et al., 1994).
As children mature, they are often included in the health care
decision making process. The older a child gets, the more likely they are to
grasp the intellectual concepts that are key in making these decisions. They
are also likely to have increased psychosocial skills as they get older. It is
generally accepted that “as soon as children are able to communicate and
participate in decisions that affect them, they should be encouraged to
participate in all aspects of the decision making process” (Borry, 2009). It is
therefore important to involve children as well as their guardians in
22

counseling and information giving sessions. It would be reasonable for
parents to defer genetic testing until their child is old enough to have active
participation in the decision.
Multiple issues arise when considering genetic testing in minors.
Test results may impact several areas of an individual’s life including
decision making, reproductive decisions, education, occupation, insurance
coverage and overall lifestyle. Genetic test results may impact family
dynamic or impose guilt or anxiety on family members (ACMG/ASHG,
1995). Testing in minors denies the rights of these individuals to make an
autonomous decision to be tested when they reach adulthood. Individuals lose
confidentiality of results from family members when they are tested as minors
(Andrews et al., 2006).
Wertz et al. (1994) set forth several reasons against testing presymptomatic children for genetic conditions. They claim that children with a
positive test may be made a scapegoat of their test results, and the test results
could cause adverse effects to that child’s self esteem. For example, the test
results could cause the child to feel unworthy and the parents to lower their
expectations for the child. The authors also speculate that test results could
disrupt family functioning, causing disharmony in parent-child and sibling
relationships. Finally, the authors are concerned that test results could evoke
feelings of guilt (Wert et al., 1994).
Many individuals from a wide range of specialties have voiced their
opinions regarding predictive testing in asymptomatic minors. Clarke et al.
(1995) have concerns that test results may result in parents feeling
23

disappointment or rejecting the child. Several individuals have expressed
concern that knowing a child had a cancer predisposition syndrome would
raise anxiety in both parents and the child (Clarke, 1994) (American Medical
Association, AMA ,1995) (Duncan et al., 2001). Other studies, however,
have shown that parents are interested in having genetic testing in their
children so they can plan for their child’s future (Wertz, et al., 1994).
Several studies have looked at many aspects of predictive
testing in children. Yet none have examined feelings that parents with LiFraumeni Syndrome may have towards genetic testing in their children.
Patenaude et al. (1996) interviewed 47 mothers of children who were
diagnosed with cancer. Given a scenario of a hypothetical test that could
detect cancer susceptibility, 13% of participants reported they would decline
having their child tested due to a lack of family history or preventative
measures. Mothers were concerned about the anxiety they might encounter
from learning that a healthy child carried a cancer susceptibility mutation.
Thirty six percent of participants would agree to have their child tested only if
knowledge of the results would reduce the risk of cancer development. Fiftyone percent of mothers would wish to have their child tested for the cancer
susceptibility gene, despite the lack of potential benefit. Mothers reported that
they would feel significantly less depressed or anxious if their child did not
have a cancer susceptibility gene. Alternatively, they did report that they
would experience depression and anxiety if a healthy child tested positive for
a cancer susceptibility syndrome. Eight percent of mothers said they would
not test their healthy children. Mothers had several reasons for this, including
24

their wish to defer the decision to test for their child and fear of insurance and
social discrimination (Patenaude et al., 1996).
The researchers then looked at factors that are important mothers’
decision to pursue genetic testing in their children. Mothers appeared to be
consistent regarding what they valued in a genetic test. The most common
aspects of a genetic test that mothers considered include utility of results and
their ability to manage health and test reliability. Mothers were also
concerned about privacy, insurance discrimination and family disruption.
(Patenaude et al., 1996). These themes appear to be similar to other
hereditary cancer syndromes.
Few reports have been published concerning clinicians’ experience
with testing minors for LFS. Evans, Lunt, Clancy and Eeeles (2009) depicted
their experience with testing four children in two LFS families. They reported
on two families, “Family 1” and “Family 2”. Three children were tested in
family 1, one set of siblings and the siblings’ cousin. The siblings both tested
negative for the pathogenic mutation that had been identified in the family.
These siblings’ parents reported feelings of relief upon hearing the test
results. The father of the siblings’ cousins was very anxious about that chance
that his child could have a pathogenic mutation, especially after several recent
deaths and cancer diagnoses in the family. Unfortunately, this child did have a
pathogenic mutation. Following the test result, the child’s father did report a
decline in anxiety despite these results. This child was gradually introduced to
Li-Fraumeni syndrome and is now an adult considering preimplantation
genetic diagnosis (Evans, et al., 2009).
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In “Family 2”, the patient was a nine year old girl who had an
extensive family history of LFS, including a brother who was diagnosed with
a cerebral primitive neuroectodermal tumor at ten and died shortly after. A
p53 mutation had been identified in the patient’s mother after she had
developed three primary tumors. The patient’s mother was very anxious
regarding her healthy child’s genetic status and reported that knowledge of
this would help her manage her daughter’s health. After several counseling
sessions, the patient underwent genetic testing and was negative. The family
reported being content with the counseling process. No follow up studies have
looked at the children’s attitudes towards having been tested at a young age.
The authors of this article emphasize the point that until there are proven
medical and psychological benefit to the child, genetic testing decisions for
LFS should be made carefully on a case by case basis (Evans et al., 2009).
No studies have examined the emotional impact genetic testing for
LFS has on children. Familial Adenomatous Polyposis (FAP) is a cancer
predisposition syndrome that, like LFS, confers a childhood cancer risk.
Unlike LFS, there are proven beneficial screening modalities in minors with
FAP. Children with FAP should begin colonoscopy and sigmoidoscopy at
ages 10 to 11 to evaluate for polyposis (Rozen & Macrae, 2006). In 2001,
Michie et al. studied the emotional impact genetic testing for FAP has on
minors. The investigators studied 60 asymptomatic children at risk for FAP
who had undergone genetic testing. They looked at factors such as anxiety
and depression. Children who received positive results had a normal range of
anxiety and depression, although they tended to be more anxious and
26

depressed than children who received negative results. The study also
explored the difference in anxiety and depression between children and adults
receiving genetic test results. The group did not find a significant difference
in either variable between the two groups (Michie, Bobrow& Marteau, 2001).
In this study, children did not appear to have exaggerated adverse emotional
impact.
Hereditary Breast and Ovarian Cancer Syndrome (HBOC) is a
hereditary cancer predisposition syndrome which predisposes individuals to
breast and ovarian cancer (often premenopausal). HBOC does not confer a
risk of childhood cancer. Genetic testing is therefore not recommended until
adulthood. In 2008, Bradbury et al. surveyed a cohort of parents and offspring
with HBOC about their attitudes towards testing minors. Fifty two percent of
participants reported that they were opposed to testing minors for HBOC,
some participants felt that genetic testing was only appropriate in minors in
special scenarios. Individuals who were in favor of testing cited
implementation of health management guidelines specific to patients with
HBOC. Although HBOC is clearly very different than LFS, it is interesting to
see that 48% of these participants are in favor of testing minors, even though
HBOC does not confer a childhood risk of cancer (Bradbury et al., 2008).
Li-Fraumeni Syndrome clearly meets the testing criteria of
conferring a cancer risk in childhood. However, there are no proven benefits
to implementing screening for cancer in children with Li-Fraumeni
Syndrome. Due to this discrepancy, testing in children is controversial and
not standard of care. Currently, in LFS, there are no data looking at parental
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attitudes towards predictive testing in children. Recently, there has been a
movement of practitioners testing children for p53 mutations. If the trend in
testing minors for p53 mutation continues, it is important to describe parental
attitudes and beliefs towards predictive testing in their children.
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MATERIALS AND METHODS
This was a cross-sectional pilot study aimed at describing the attitudes of parents
of children at risk of inheriting a p53 mutation toward genetic testing in their children.
This study was approved by MD Anderson Cancer Center’s Institutional Review Board
(BS99-038) and the Committee for the Protection of the Human Subjects at the
University of Texas Health Science Center (HSC-GEN-09-0415).

Study Population Identification and Recruitment
Individuals who had previously participated in LFS genetics research at the
University of Texas MD Anderson Cancer Center (MDACC) were recruited for the
study. The recruitment source was a research database that included data from families
with Li-Fraumeni Syndrome and was maintained by the Department of Genetics at
MDACC. The database includes 73 kindreds, and we identified 371 living individuals
who were at 25% or greater risk of carrying a p53 germ line mutation or who were
known p53 mutation carriers. Individuals were eligible for the study if they were: 1) a
parent of a child younger than 27 years of age who was at risk of inheriting Li-Fraumeni
Syndrome or previously diagnosed with a LFS-associated cancer, 2) 18 years of age or
older, and, 3) able to speak, read, and write English.
Fifty six individuals were identified as being eligible for the study. Valid mailing
addresses were available for 20 of the eligible individuals. We also identified an
additional 25 deceased individuals from the database who were confirmed or presumed
p53 mutation carriers, whose children met the above eligibility criteria, and who had a
surviving co-parent. Of these 25 individuals, 5 mailing addresses were available for
surviving co-parents.
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Data Collection
Study packets were mailed to 25 eligible individuals and included a cover letter, a
consent form, a study questionnaire, and a postage-paid return envelope. The cover letter
included a description of the study and an invitation to participate, as well as instructions
for completing and returning the questionnaire. In the event that the individual in our
LFS database was deceased, the co-parent was instructed to complete the survey. Coparents were given the same survey packet as LFS-affected parents. Co-parents were
defined as a surviving spouse of an individual with LFS who is deceased. Parents were
instructed to complete the written informed consent prior to completing the study
questionnaire, and to return both the consent form and the completed questionnaire in the
return envelope.
The study was conducted from December 2009 to March 2010. Study packets
were mailed in mid-December 2009, and follow-up packets were mailed to nonrespondents at 3 and 6 weeks after the initial mailing. At 4 weeks post-initial mailing, we
attempted to contact non-responders by telephone to follow up and invite them to
complete the questionnaire by phone, if they preferred. Three study packets were returned
without a forwarding mailing address, and one study packet was returned because the
intended recipient had passed away. Thus, our denominator of eligible individuals was
reduced to 21.

Measures
The selection of study measures was based on several key domains in pediatric
genetic testing, including attitudes towards p53 genetic testing, communication about
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testing, stage of change (or readiness) regarding genetic testing, and decisional balance
(consideration of pros vs. cons). Measures regarding parental communication about
genetic testing as well as attitudes and beliefs related to testing were adapted from
existing instruments used in other studies (Andrews et al., 2006)( Peshkin et al., 2008)(
Peterson et al., 2008)(Terycak et al., 2001 ). Additional measures were created
specifically for this study based on domains in the pediatric genetic testing literature.
The survey was organized into three sections and encompassed the following six
domains: 1) general attitudes, 2) communication, 3) stage of change, 4) decisional
balance for parents who have sought testing, 5) decisional balance for parents who have
not sought testing, and 6) demographics. We estimated that the study questionnaire took
about 30 minutes to complete. No compensation was provided for study participation.

Attitudes toward genetic testing in children
We included three measures regarding attitudes and interest in genetic testing in
children. We used the Pediatric Testing Attitudes Scale (P-TAS), an 11-item validated
measure developed by Peshkin and colleagues (2008). P-TAS was created to determine
the interest of parents with BRCA1/2 mutations towards genetic testing in their children.
The P-TAS measures two factors along this dimension: Attitudes and Beliefs (factor 1)
and Decision Making and Communication (factor 2). The P-TAS includes 11 statements
describing attitudes toward testing children for a BRCA1/2 mutation, and respondents are
instructed to rate each item on a scale of 1 to 5 (1=strongly against genetic testing in
minors to 5=strongly in favor of it). Participants were also given the option of “unsure”
(6). Score are obtained by summing the individual items. “Unsure” responses were not
counted in the total P-TAS score. For the present study, we revised the statements to
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reflect attitudes towards p53 genetic testing. Higher P-TAS scores were indicative of
individuals who were in favor of genetic testing in minors, while lower scores were
indicative of individuals who opposed genetic testing in minors. Our second measure was
a seven item questionnaire developed specifically for this study. We developed seven
scenarios when p53 genetic testing may be considered in minors. The participants were
instructed to determine whether in each scenario, they would pursue genetic testing in
their child. Participants were given the options of “yes”, “no” and “unsure”. Finally, we
included a single item measure aimed at determining at what age the participant thinks
testing should be considered in minors. This item was initially used in a similar study
looking at parental attitudes towards testing minors for familial adenomatous polyposis
(FAP) (Andrews et al., 2006).

Communication with children regarding p53 genetic testing
We included a measure adapted from Tercyak et al. (2001) to characterize how
parents communicated with each child regarding Li-Fraumeni Syndrome and p53 genetic
testing. This measure was originally developed to evaluate communication between
mothers with BRCA1/2 mutations and their children about genetics and testing. The
measure included four topics regarding communication with children about genetic
testing. Individuals were asked how frequently they discussed these four topics with their
child and how comfortable they felt about it. Items were scored on a scale of 1 to 4 (1=
not at all, 4= often) (1= not at all, 4 = very). Lower scores indicated less communication
with children about genetic testing, and higher scores indicated greater communication.
Two scores were given: 1) communication with child and 2) comfort with
communication with child.
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Trans-Theoretical Model
The Trans-Theoretical Model (TTM) is a psychological and health behavior tool
that measures and individual’s readiness to implement a behavior (Prochaska &
DiClemente, 1983) (Prochaska, DiClemente & Norcross, 1992)( Prochaska & Velicer,
1997). This model, which focuses on the decision making of an individual, consists of
five “core constructs”: 1) stage of change, 2) process of change, 3) decisional balance, 4)
self- efficacy, 5) temptation (Prochaska & Velicer, 1997). In this study, we utilized “stage
of change” and “decisional balance” measures to explain attitudes respondents had
towards predictive p53 genetic testing in minors. A consistent pattern has been observed
between the relationship of decisional balance and stage of change (Prochaska & Velicer,
1997).
Stage of Change
Stage of change is one of five “core constructs” of the Trans-Theoretical Model
(TTM) (Prochaska, Velicer, 1997). It consists of five discrete levels of behavior change
or adoption: 1)pre-contemplation 2)contemplation 3)preparation 4) action 5)maintenance.
We ascertained the steps each parent had taken towards seeking genetic testing for their
child. Scores were based on a 1 to 5 scale. Individuals were given the option of “I have
no interest in this”, “I haven’t thought about it”, “I have thought about it”, “I am
committed to it”, and “I have already done it”. Low scores were indicative of individuals
who have taken no or few steps towards obtaining genetic testing in their child while high
scores correlated with individuals who have been active in seeking genetic testing for
their children.
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Decisional Balance
The decisional balance measure is one of five “core constructs” of the TTM
(Prochaska, Velicer, 1997). The items were aimed at determining decisional balance
(pros and cons) regarding desire to obtain genetic testing in their children. Items were
adapted from past studies (Vernon et al., 1999)(Peterson et al., 2008) looking at genetic
testing attitudes. These items were initially created based on patient and health care
professional experience (Vernon et al., 1999). Individuals who have and have not had
their children tested for p53 mutations were asked to rank the important four “pros” and
“cons” in their decision to pursue/decline predictive p53 genetic testing in their children.
Answers were based on a 1 to 5 point Likert scale (1= not important, 5= very important).
We aimed to determine how each participant prioritized the positive and negative
components of predictive p53 genetic testing in minors.

Demographics and Family History
We assessed participants’ demographic characteristics including gender, marital
status, education, occupational status and household income. Additional demographic and
family history information such as age, race, ethnicity and family history of LFS-related
cancer and death was obtained through existing information in the MDACC database.

Data Analysis
Data were entered into an excel spreadsheet. Descriptive statistics were run on the
data. We first analyzed each individual participant’s responses. The participants were
then analyzed as a group. Next, we divided the participants in two groups: those who
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have tested their children and those who have not tested their children. As our sample
size is small (n=6), we did not feel it was appropriate to perform statistical tests of
association or other analyses.
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RESULTS

Demographics
Of the 21 potentially reachable participants, 6 returned the survey, with a
response rate of 6/21 (28.57%). Two of the participants were co-parents, while the other
4 belonged to our original Li-Fraumeni Syndrome cohort. Three participants (50%)
were male and three (50%) female. Four individuals were married (66.67%), while the
other two were widowed. Education level of the participants varied with one completing
some high school, two completed some college, two were college graduates and one had
an upper level degree. Most individuals held either full or part time employment, while
one participant was unemployed and seeking a job. Of note, one participant was disabled
from a diagnosis of terminal cancer Annual household income ranged from $25,000$50,000 per year (50%), to >$75,000 per year. Table 1 summarizes participants’
demographic profiles.
Table 1b describes characteristics of each respondent and/or co-parent. Three
respondents were co-parents of individuals with p53 mutations who have passed away.
Of the remaining 3 participants, 2 had a p53 mutation, while 1 did not. Ages of the
respondents/ co-parents ranged from 35-52 years.
Data from 6 families with 12 children were available for study. Five of the
individuals who completed the survey had children (Table 2). The sixth participant did
not have children. On average, the families had 2.4 children, with ages ranging from 15
to 22 years. Three children from 2 families were deceased at ages 6, 9 and 23. All of
these children were reported to have died from cancer. Of the offspring reported in the
survey responses, 8 (66.67%) were female, and 4 (33.33%) male.
36

Table 1. Demographic Characteristics of Participants
Number %
Total
Participants
(N)

6

Number %
Occupation

Gender

Employed (full
time)

2

33.33%

Employed (part
time)

2

33.33%

Male

3

50%

Unemployed
(seeking job)

1

16.67%

Female

3

50%

Disabled

1

16.67%

Marital Status

Annual Household
Income

Married

4

66.67%

$25,000 – $50,000

3

50%

Widowed

2

33.33%

$50,000 - $75,000

1

16.67%

2

33.33%

>$75,000
Education
Some high
school

1

16.67%

Some college

2

33.33%

College
graduate

2

33.33%

Upper level
degree

1

16.67%
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Table 1b. Respondent characteristics
Family

Vital

Age/Age Gender
of Death

Genotype Respondent

1

Living

50

Male

Mutation

Self

2

Living

50

Female

Wild
type

Self

3

Deceased 37

Male

Mutation

Co-parent

4

Deceased 43

Female

Mutation

Co-parent

5

Deceased 35

Female

Mutation

Co-parent

6

Living

Female

Mutation

Self
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Table 2. Child information
Family

1

2

3

4

5

Child

Vital

Age Cause of death

Gender

1

Deceased

9

Unspecified cancer

Female

2

Deceased

23

Unspecified cancer

Female

1

Alive

22

NA

Female

2

Alive

21

NA

Female

3

Alive

20

NA

Female

1

Alive

20

NA

Male

2

Alive

18

NA

Male

1

Alive

20

NA

Male

2

Alive

16

NA

Female

3

Alive

15

NA

Female

1

Alive

16

NA

Female

2

Deceased

6

Unspecified cancer

Male
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6 surveys

No children
(n=1)

Children (n=5)

Tested
(n=2)
5 individuals
Not Tested
(n=3)
6 individuals

Figure 2. Survey response dichotomization

Questionnaire Response
P-TAS (Pediatric Testing Attitudes Scale)
All six participants completed section one of the questionnaire. P-TAS scoring is
based on a 1-5 scale, with lower scores indicating attitudes against testing and higher
scores indicating attitudes in favor of testing. This was an 11-item scale, scores could
potentially range from 11 (strongly against testing) to 55 (strongly in favor of testing).
The P-TAS scores from this survey ranged from 38-55, with an average of 45.833,
indicating strong attitudes towards p53 testing in children (Table 3). The creators of the
P-TAS model further divided the questionnaire into two factors, 1) attitudes and beliefs
and 2) decision making and communication. These factors are believed to assess parents’
attitudes in pediatric p53 testing. The average scores were 4.42 and 4.22 for factors 1 and
2, respectively. Scores for factor 1 ranged from 3.2 to 5, while factor 2 scores ranged
from 3 to 5 (Table 4).
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Table 3. P-TAS responses
Agr
ee

Stro
ngly
Agr
ee

1. Children under age 18 should be given the opportunity to be
tested for the p53 mutation

2
33.3
3%

4
66.6
7%

2. Parents should decide if their children are allowed to have a
p53 test or not, even if a doctor disagrees

1
16.6
7%

4
66.6
7%

1
16.6
7%

1
16.6
7%

4
66.6
7%

Stro
ngly
Disa
gree

Disa
gree

3. Even though some of the cancers associated with p53
mutations do not affect children until they reach adulthood,
children should still be offered p53 testing

Neit
her
Agr
ee
nor
Disa
gree

4. Children should be involved in making the decision about
whether or not they participate in p53 testing

1
16.6
7%

1
16.6
7%

1
16.6
7%

3
50%

5. If children are tested and they carry a p53 mutation (that is,
they test positive), they should be told about their test result
immediately

1
16.6
7%

2
33.3
3%

2
33.3
3%

1
16.6
7%

6. Even if there is no known prevention, treatment, or cure for
the cancers associated with p53 mutations, children should be
offered p53 testing

3
50%

3
50%

7. If children are tested and they turn out to carry a p53
mutation (that is, they test positive), then this information
should be shared with the child’s pediatrician.

2
33.3
3%

4
66.6
7%

1
20%

3
60%

1
20%

1
20%

2
40%

2
33.3
3%

1
16.6
7%

3
50%

1
20%

8. I want my child to be tested for a p53 mutation before age 18
*
9. If children are tested and they do not carry a p53 mutation
(that is, they test negative), they should be told about their test
result immediately *

1
20%

10. The benefits of children participating in p53 genetic testing
outweigh the risks

11. I am in favor of p53 gene testing for children

1
16.6
7%

4
66.6
7%

Uns
ure

1
16.6
7%

1
16.6
7%

40

Table 4. P-TAS and Factor Analysis
Family

Total

Factor 1

Factor 2

P-TAS

(average)

(average)

1

52

5

4.4

2

46

4.5

4.75

3

42

3.83

3.75

4

42

5

3

5

55

5

5

6

38

3.2

4.4

4.42

4.22

Average 45.833

Chart 1. P-TASScores
60
55

55

52
50
46

46
42

42

40

38

30

20

11
10

Family
0
1

2

3

4

5

6

Average

In favor

Against
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1.2

Chart 2. P-TASFactor Scores
1.00

1.00

1.00 1

1
0.88

0.90

0.88

0.77
0.76

P-TASRatio

0.8

0.76

0.6

0.53 Factor 1
0.48

Factor 2

0.4

0.2

0
1

2

3

4

5

6

Family

Scenario Decision Making
Participants were given a scenario and asked if they would be in favor of p53 gene
testing for their child. All participants indicated that they would be in favor of testing if
any of their children had developed cancer, if the results would help manage the health of
that child or help another family member in any way. Most individuals (n=4, 80%) would
be in favor of testing if the child agrees to or requests testing, while one was unsure. Table
5 summarizes these results.
Participants varied when asked at what age it is appropriate to test a child for a p53
mutation. Responses included numerical responses such as 13, 18 or 21.
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Others made comments such as “ASAP” and “As early as possible without
child knowing, one or above”. Table 6 summarizes these results.

Table 5. Scenario Decision Making
Yes
n
My child has
developed cancer

5

One of my other
children has developed
cancer

5

He/She agrees to have
testing

4

He/She requests testing

4

He/She is older than
ten

3

Unsure
%

n

%

100%

100%

If the results would
help manage my
child’s health

5

If results would help
other family members

5

80%

80%
60%

1
1
2

20%

20%
40%

100%

100%
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Table 6. Age of testing responses
Family

At what age do you feel it is appropriate to test
an individual for a p53 mutation?

1

ASAP

2

No answer

3

Should be based on the individual child. Too many
variables to establish one specific age.

4

As early as possible without child knowing. One or
above.

5

13

6

18 or 21, depends on the child (adult)?

Communication
Communication was characterized by a model created by Tercyak et al. (2004).
Individuals were asked how frequently they discussed topics pertaining to p53 mutations
and genetic testing and how comfortable they were with this discussion (or lack thereof).
Five individuals completed this section for a total of 11 children (Table 7). Three parents
reported sometimes talking to their children about p53 genetic testing, while 2 parents have
never had this discussion. Of the individuals who have spoken with their children about
this issue, all of them felt either mostly or very comfortable with it. Only two parents have
asked children how they felt about genetic testing often, one individual reported having
this discussion sometimes, while two parents never have had this conversation. All of the
individuals who have asked their child their feelings towards p53 testing felt either mostly
or very comfortable with the discussion. Most participants’ responses did not vary
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between children. One participant (4) did vary their responses between his/her three
children. It is unclear why these results are discrepant.
Stage of change
Five participants with a total of 11 children completed the stage of change
questionnaire. Participants varied regarding the steps they have taken towards seeking
genetic testing for their child. Two individuals have reportedly had p53 genetic testing on
all of their children (n=3) and shared the child’s results with him/her. Others have thought
about (n=2) or are committed to (n=1) discussing p53 genetic testing with their child and
seeking more information about the subject. One individual has reportedly not thought
about seeking information or meeting with someone to discuss p53 genetic testing. One
individual is committed to have their child tested for a p53 mutation, while two individuals
have thought about it. Individuals gave consistent answers for each of their children. Table
8 reviews these responses.
Testing motivations – child tested
Two of the five participants have sought genetic testing for their children (n=3).
Table 9 depicts their responses to the testing motivation questionnaire. Family number one
reported testing both of their children prior to their death. Family 1 reported that the
possibility of relief to know that their child did not have a p53 mutation was “important”,
while family number two ranked it as “very important”. Both families ranked their
family’s experience with cancer and the level of concern about their child it has caused as
“very important”. Likewise, both families ranked the possibility of their child undergoing
preventative measures or planning for their future as “very important”. Participants’
responses did not vary between children.
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Testing motivations- child not tested
The three families whose children have not had p53 genetic testing answered
similar questions about what their motivations would be towards seeking testing (table 10)
Family 3 ranked relief from knowing their child does not have a mutation as “slightly
important”, while families four and five ranked it as “very important”. Family 3 said that
their family’s experience with cancer making them more concerned is “somewhat
important”, while families 4 and five ranked family experience with cancer as “very
important”. The chance that their child could do something to lower his/her risk was
“somewhat important” to family 3, “important” to family 4, and “very important” to family
5. Family 5 thought that the possibility that they or their child could plan for the child’s
future was “very important”, family 3 thought it was “somewhat important”, and family 4
thought it was “slightly important”. Participants’ responses did not vary between children.
Family 6 did not complete this questionnaire because they do not have children.
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Table 7. Communication
How often have you:
Not
at

How comfortable were you with this?

Rarely
Not

SomeOften

all

times

A
little
bit

Mostly

Very

4(2,3)*

3,5

1,2

at
all

Talked with
this child
about
genetic
counseling
and testing
for p53?

3,4

Asked this
child how
he/she felt
about
genetic
testing?

3,4

1,5

4(2,3)*

2,3,4(1)*

1,5

4

1,2,5

4(2,3)*

4(1)*

1,2,5

1,2,5

4(2,3)*

3,4(1)*

1,2,5

Tried to
reassure this
child that
he/she
would be
OK?

1,2,5

2

**
Tried to
reassure this
child YOU
would be
ok?

4

3

*Parenthesis indicate instances when individuals responded differently for each child.
Numbers inside parenthesis represent which child each response was intended.
** Participant 3 did not respond to this item
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Chart 3. Communication Scores
35

32

32

31
29

30
25

23

20
15

13

12

10

8

5
0
1

2

3

4

5

Average Minimum Maximum

Table 8. Stage of Change

n= 5 families (11
children)

I have
no
interest
in this

I haven’t
thought
about it

n

n

%

%

Discussed genetic
testing with this child

I have
thought
about it

I am
committed to
it

I’ve already
done it

n

%

n

%

n

%

2

40%

1

20%

2

40%

1

2

40%

Sought information
regarding testing for a
p53 mutation in this
child

1

20%

1

20%

Made an appointment
with a doctor/genetic
counselor

2

40%

1

20%

2

40%

Met with a
doctor/genetic
counselor

1

20%

2

40%

2

40%

2

40%

Had this child tested for
a p53 mutation
Shared these results

20%

1

20%

2

40%

1

33.33%

2

66.67%
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Testing concerns
Five families with a total of eleven children completed the “testing concerns”
section of the questionnaire. Participants were asked to rank the importance each factor
was/is when considering pediatric genetic testing (Table 11). Most individuals (n=4) stated
that the concern that they or their family would get too upset about test results was “not
important”, while one individual ranked it as “somewhat important”. The concern that their
child would get too upset was somewhat important to three individuals and slightly
important to two individuals. The majority of participants (n=4) cited concern about
insurance discrimination and test results affecting their child’s future as “very important”.
Participants responses regarding the lack of management or prevention techniques for
individuals who have p53 mutations varied from “not important” (n=1), “somewhat
important” (n=1) and “very important” (n=2). Most of the participants’ responses did not
vary from child to child. One individual did vary their responses between children.
In addition to the quantitative results previously discussed, our questionnaire
included several opportunities for respondents to provide additional comments. Table 11
consists of comments the respondents shared with us in open-ended opportunities.
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Table 9. Testing motivation (tested)
n=2 families , 5 children

I would have been relieved to know
that my child did not have a p53
mutation
My family’s experience with cancer
made me more concerned about my
child’s own risk for the disease
My child could do something to
lower his/her cancer risk

Important

Very
Important

Fam. 1

Fam.2
Fam. 1
Fam.2
Fam. 1
Fam.2

I / My child could plan for the future

25

20

Fam. 1
Fam.2

Chart 4. Decisional Balance: Pros
19

20

20

20
17.134

15.67

Score

15
11

10

4

5

0
1

2

3 Family

4

5

Average

Minimum

50

Maximum

Table 10. Testing motivations (not tested)
Slightly
Somewhat
Important
Important
n=6 children from 3
families
I would have been
relieved to know that
my child did not have a
p53 mutation
My family’s experience
with cancer made me
more concerned about
my child’s own risk for
the disease
My child could do
something to lower
his/her cancer risk
I / My child could plan
for the future

n

%

3

33.33%

4

33.33%

n

%

3

33.33%

3

33.33%

3

33.33%

Important

Very
Important

n

n

%

4,
5

66.67%

4,
5

66.67%

5

33.33%

5

33.33%

4

%

33.33%
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Table 11. Testing concerns
n=5
families, 11
children
I’m afraid I
would get
too upset
I’m afraid
my child
would get
too upset
I am
concerned
that having
the test
might cause
problems
with my
child’s
insurance
There is
nothing my
child can do
about
getting
cancer
I am
concerned
about my
family’s
reaction
I am
worried
about how
it could
affect my
child’s
future

•

Not Important

1,2,3,4

Slightly
Important

80%

1,3

1,4

40%

1,3,4,5

80%

2

40%

Somewhat
Important

Important

Very Important

5

20%

2,4,5

60%

1

20%

2,3,4,5

80%

3

20%

2,5

40%

3(1)*

10%

1,2,4,5

80%

20%

3(2)*

10%

Parenthesis indicate instances when individuals responded differently for each
child. Numbers inside parenthesis represent which child each response was
intended.
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Chart 5. Decisional Balance: Cons
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Chart 6. Decisional Balance: Pros vs. Cons
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0
1

2

3 Family

4

5
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Table 11. Additional Comments
Family Comment
1

Info is power

3

I have not had my children tested because their father's opinion/request
was not having them tested. He felt that being aware of the risks and
having regular checkups would be a better option. He feared if they were
tested positive, it could have adverse affects. I.E. ability to get health or
life insurance, psychological since their father lost his battle with cancer,
etc. As young adults I need to educate them with their options and allow
them the choice at some point
I want to know as a parent. My kids already know they are at a greater
risk because of being related to my wife's family. I do not want them to
know results until all 3 are ready as adults. I do want their doctors to
know.

4

I do not want my kids to know results or even what the test is looking for
until all 3 are adults or if one develops cancer. If one finds out, the others
will worry.
I don't want my kids to know results or even the real reason for the test
other than testing them is for research. Would prefer if draw made by
family doctor as "routine" blood work. I do want to know and I also want
my family doctor to know (verbally).
It would justify testing that could give early detection, allowing better
odds on treatment.
5

We have recently been discussing with (proband’s)15 year old daughter
about getting her tested for (LFS).
We are living with the effects that losing a mother and a brother because
of (LFS), has on a child. The worries and the fears that are created when
she is ill or just doesn’t feel good. (Daughter) is constantly worried
about developing cancer and it has created a major impact on all of our
lives.
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Discussion

Pre-symptomatic testing for p53 mutations is clinically available and the choice to
test a child for these mutations is typically left to the parents and physician of the child.
The decision whether to have a minor-aged child tested for a cancer predisposition gene
such as p53 is composed of several factors (Patenaude et al., 1996). This study looks at
parental attitudes towards testing children for p53 mutations. We looked at factors such as
basic attitudes towards genetic testing, communication with children and used the Transtheoretical model to assess decisional balance and stage of change. This is the first study to
examine the attitudes of parents towards testing their children for p53 mutations.
Demographics and family characteristics
The demographic characteristics of our participants appear to be unremarkable.
Among the six respondents, there is no clear pattern in terms of gender, marital status,
education, employment our annual household income. Age of respondents also appeared to
be insignificant. Of note, the survey was sent to households with children who are a variety
of ages. All of the participants with living children who responded had children between
15 and 23 years of age. It is interesting that no individuals with younger children chose
respond to the study. The average age of living children to individuals who did not
respond to the survey was 17.4 years with ages ranging from 1 to 35 years.
Questionnaire
Pediatric Testing Attitudes Scale (P-TAS)
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The pediatric testing attitudes scale (P-TAS) is a measure developed my Peshkin et
al. (2009) to ascertain parental attitudes towards testing minors for BRCA1/2 mutations.
This eleven-item scale was divided by its creators using principal components extraction
method with rotation of factors in two factors: 1) attitudes and beliefs (six items), and 2)
decision making and communication (five items). Scores from each factor were summed to
give the total P-TAS score for each participant with a minimum of 11 and maximum of 55.
Higher scores were indicative of parental attitudes more strongly in favor of pediatric p53
genetic testing, while lower scores indicated parents who were more opposed to testing
their children for p53 mutations.
Scores from our six participants ranged from 38 to 55 with an average of 45.833.
These scores indicate that parents were mostly in favor of obtaining p53 genetic testing for
their children, although scores varied. When scores are divided into their two factors, an
interesting observation can be made. Factor 1 is composed of 6 items regarding attitudes
and beliefs about p53 genetic testing in minors, with a minimum and maximum score of 6
and 30, respectively. The average factor 1 score from our six participants is 26.
Respondents seem to be consistently “in favor of”, or “strongly in favor of” most items
regarding minors having the opportunity to be tested for p53 mutations. Sample items from
factor 1 include: “children under age 18 should be given the opportunity to be tested for
the p53 mutation”, and “even if there is no known prevention, treatment, or cure for the
cancers associated with p53 mutations, children should be offered p53 testing”. Only one
individual reported that they did not want their children tested for p53 mutations before the
age of eighteen, although they appeared to believe that children and parents should be
given the opportunity to make that decision. In total, parents seemed to agree that all
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children should have the right to be tested for p53 mutations, although not all would
personally test their child or children.
Factor 2 pertains to decision making and communication (Peshkin et al., 2009).
Sample items from factor 2 include statements such as: “Children should be involved in
making the decision about whether or not they participate in p53 testing” and “If children
are tested and they turn out to carry a p53 mutation, they should be told about their test
result immediately. Factor 2 consisted of five items which were totaled to make a
minimum and maximum score of 5 and 25, respectively. Respondents’ factor 2 scores
ranged from 12 and 25 with an average of 19.83. Individual responses to these items
varied. While most people believed that parents should be able to make the decision to test
their child for a p53 mutation, respondents did not agree whether children should be
involved in the decision making process. One individual strongly disagreed that children
should take a part in this decision, while others were either unsure or agreed. That same
individual was strongly against sharing the child’s genetic testing results with him/her
regardless of if the testing identified a mutation. This respondent did, however agree that
the information should be shared with the pediatrician. While some individuals would
apparently readily involve their child in the testing decision, others would prefer to make a
decision on behalf of their child.

Testing Scenarios
All participants reported that they would test their child for a p53 mutation if that
child had developed cancer, or if the child’s sibling developed cancer. Other studies have
demonstrated that parents would be more likely to test a child who has already developed
cancer for a cancer susceptibility gene, than a healthy child (Patenaude et al., 1996). The
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question of pre-symptomatic testing in minors becomes more complex. Four individuals
would test their child if the child consented to or even requested testing, while one was
unsure. Three individuals would test their child if he/she was over the age of ten, while
others were unsure. Finally, all individuals would test their child for a p53 mutation if
results would help manage that child’s health or help other relatives. Although the option
of “no” was given, respondents never chose it for any of the seven scenarios. Parents most
likely recognize that the decision to test their child for a p53 mutation is composed of
several factors which must all be considered in light of each child/family’s unique
situation.

Age
Parents varied in their response regarding the appropriate age would be to test
children for a p53 mutation. Family 1, who had two children die from cancer related issues
reported that he thought children should be tested for p53 mutations as early as possible.
Family 4 agreed that children should be tested as early as possible but added that the child
should not know about the test or results. Family 4 is consistent throughout the survey in
their attitude about not wanting their children to know the results of the test. Family
number five believes children should be tested at age 13. At this age, minors are often
thought to be able to make their own meaningful decisions, and it may therefore some may
consider it reasonable to allow these children to participate more in their healthcare
decisions. Family 3 reported that the age to test a child for p53 mutations “should be based
on the individual child” and that there are “too many variables to establish one specific
age”. This statement may refer to the fact that children, regardless of age have varying
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cognitive abilities, maturity, and decision making capabilities. Some mature adolescents
may have the same mental capacities that are associated with autonomous agents (Kon,
2006), while others may not. Other factors such as health of the child and their siblings,
family history and other psychosocial characteristics that are unique to that child may also
play a role in a parent’s decision of when to test their child. Family 6 stated that
individuals should be tested for p53 mutations at the age of 18, or 21, depending on the
individual. This individual seems to be taking a more conservative stance on genetic
testing and believes that it should be postponed until the child has reached the age of
majority (18 in most states) or age of license (varies) . The age of majority refers to the age
at which a child transitions to an adult and assumes responsibility of his or her own self,
decisions and responsibilities. At this age, the child is no longer under jurisdiction of their
parent or guardian. Age of license refers to the age at which an individual gains certain
privileges. For instance, 21 is often the age of license for consumption of alcoholic
beverages and participation in gambling activities. Family 6 appears to associate these ages
with the ability of an individual to make reasonable and well thought decisions about their
healthcare.
Communication
Past studies indicate that the frequency of communications parents have with their
children about family history of cancer, genetic testing and general child and parental
health correlates with interest in genetic testing and disclosure of results (Terycak et al.,
2002)(Tercyak et al., 2006). Overall, families varied in regard to how frequently they
communicated with their children about these issues. Families 3 and 4 were consistent
non-communicators. They do not appear to have open communication with their children
with regard to genetic testing and parental/child health. Family 4 appears to be fairly
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consistent in their attitudes about not wanting to involve their children in any of the
decision making processes of genetic testing. While family 3 did not make any other
revealing comments about not wanting to involve their children in the decision to test, they
do not appear to be having active discussions about the issue.
Other families reported that they sometimes spoke with their children about genetic
counseling and testing for p53 mutations and felt mostly or very comfortable with it. These
individuals also sometimes or often asked their child how he/she felt about genetic testing
and seemed comfortable with those discussions. These families seem to have open
communication with their children about p53 genetic testing and most likely their child’s
input. Most individuals report frequently reassuring their child about their own health and
that child’s health. Those who have this discussion appear to be fairly comfortable with it.
Although our sample size is small, the results are consistent with research done by Tercyak
et al. (2002). The two families who have already had their child tested for p53 genetic
mutations appeared to be very open with their children about p53 genetic testing. Others
who reported less frequent communication with their children have not taken steps towards
seeking testing in their children.
Trans-theoretical Model
The trans-theoretical model (TTM) has been used extensively in health-related
studies looking at intentional behavior change (Prochaska & DiClimente, 1983)
(Prochaska, DiClemente & Norcrow, 1992) (Prochaska & Velicer, 1997). The model is
composed of five core constructs: 1) stages of change, 2) processes of change, 3)
decisional balance, 4) self-efficacy and 5) temptation (Prochaska & Velicer, 1997). In our
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study, we used the stage of change and decisional balance measures to explain attitudes
towards p53 genetic testing.
Stage of Change
The stage of change measure is composed of a series of five changes: 1) precontemplation, 2) contemplation, 3)preparation, 4) action and 5) maintenance (Prochaska
& Velicer, 1997). Pre-contemplation refers to the stage when individuals do not intend to
make an action in the next 6 months (Prochaska & Velicer, 1997). In our questionnaire, the
pre-contemplation stage is represented by two items: have individuals discussed testing
with their children and have they sought information regarding testing. All of the
respondents have at least considered talking with their children about genetic testing. Some
answers to this section were not consistent with respondents’ answers to the
communication measure. Only two individuals reported that they have already discussed
genetic testing with their child, while three individuals reported that they have sometimes
talked with their child about genetic testing in the communication measure. It is not clear
why these responses are discrepant. Individuals who are in the contemplation stage are
intending to change in the next six months (Prochaska & Velicer, 1997). In most cases,
they have thought seriously about the decision to change, such as the pros and cons.
Individuals who are in the contemplation stage in obtaining p53 genetic testing for their
children have presumably sought information or made an appointment with a physician or
genetic counselor. Most families have at least thought about seeking information and
making a counseling appointment. Two families reported that they had not thought about
seeking information about testing, while one has not thought about making a genetic
counseling appointment. These individuals do not appear to be seriously considering
genetic testing in their children, although in previous sections of their survey, they
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appeared to be in favor of pediatric genetic testing in minors. The preparation stage refers
to the stage when people plan on taking action in the immediate future (Prochaska &
Velicer, 1997). In our study, individuals who have met with a physician or genetic
counselor were in the preparation stage. Only two individuals reported that they have met
with a physician/genetic counselor, while the rest have either not thought about it, or have
thought about it and not acted on it.
Only two individuals (families 1 and 2) have had their children tested for p53
mutations, thus completing that action stage (the stage in which people have implemented
a change or action) (Prochaska & Velicer, 1997). One family is committed to this, while
two have thought about it. Both individuals who tested their children have disclosed the
results to those children. Another individual is committed to sharing genetic results with
their child once that child gets tested. Overall, only two individuals have gone through all
of the stages of change and even disclosed results to their children. Others appear to be still
in the pre-contemplation stage. Among those in the pre-contemplation stage, some
individuals seem to be more interested in genetic testing than others, by saying that they
are committed to having their child tested for a p53 mutation and disclosing those results.
Other families do not appear to have contemplated to subject.
Decisional Balance
Decisional balance refers to the weighing of pros vs. cons of implementing a
behavior or change (Prochaska & Velicer, 1997). How an individual weighs the pros and
cons of a decision is thought to predict their stage of change. For instance, a person who is
only in the contemplation stage might rate the pros and cons equally, while someone who
is in the action stage might rate the pros higher than the cons. If this is true, individuals
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who have tested their children for p53 mutations should have higher “pros” scores than
“cons” scores. In fact, this is the case. The pros scores for families 1 and 2 are 0.95 and
1.0, respectively, while the cons are 0.52 and 0.84. Both families seemed to value the pros
more than the cons. Likewise, individuals who are still considering p53 genetic testing
should have a near balance of “pros” and “cons”. Families 3,4 and 5 had “pros” scores of
0.55, 0.8, and 1.0, respectively and “cons” scores of 0.62, 0.64 and 0.84. With the
exception of family 5, families 3 and 4 and lower “pros” scores than the two families who
tested their children. It is possible that they have not pursued p53 genetic testing in their
children because they do not see value in results. Family 5 has “pro” and “con” scores
identical to family 2, but has not tested their child for p53 mutations. They did, however,
indicate that they are committed to testing their child for p53 mutations and disclosing
those results to that child. The decisional balance appears to be a predictable indicator of
stage of change in this small sample.
Regardless of whether their children have undergone genetic testing, most
individuals (n=4, 80%) ranked that their family’s experience with cancer increasing their
concern about their child’s risk as “very important”. Likewise, most (n=4,80%) ranked the
relief they would feel if their child did not have a p53 mutation as “important” or “very
important”. It is interesting to note that those who tested their children for p53 mutations
ranked the possibility that test results could manage their child’s health or help plan for the
child’s future as “very important”, while only one of the individuals who have not tested
their children chose the same ranking. This is the same individual who is committed to
testing their child. Other families ranked it as “somewhat important” and “important”. It
appears that individuals who have not had their children tested for p53 mutations see a lack

63

of potential benefit for the child’s health or planning for the future. How families perceive
the utility of testing appears to influence how they weigh the “pros” and “cons”.
Families uniformly ranked the possibility that they would have a negative reaction
to test results as “not important” or “somewhat important”. Likewise, individuals were not
concerned about their family’s reaction, indicating that it was either “not important” (n=4,
80%), or “slightly important” (n=1, 20%). Families seem more concerned about the
reaction of the individual child being tested for a p53 mutation, ranking concern about the
child’s reaction as “slightly important” (n=2, 40%) and “somewhat important” (n=3, 60%).
These families appear to be taking a protective role in being concerned about their child’s
reaction over their own.
Eighty percent (n=4) of respondents ranked concern about insurance discrimination
as “very important”. This is consistent with other studies which cite concerns about
insurance discrimination as major deterrents to pre-symptomatic genetic testing.
Individuals do not appear to feel protected by the Genetic Information Non-discrimination
Act (GINA), which was implemented in the fall of 2009 (Erwin, 2009). GINA protects
pre-symptomatic individuals from discrimination by health insurance companies and
employers (Slaughter, 2008) (Erwin, 2009). GINA does not protect pre-symptomatic
individuals from life or long term disability insurance (Slaughter, 2008). It remains to be
seen whether the country’s health care reform will change how individuals feel about
insurance discrimination.
There were no clear patterns between the families who have tested their children
and those who have not in how they ranked the “cons”, with the exception of one item.
One item (there is nothing my child can do about getting cancer) was particularly varied,
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with answers ranging from “not important” to “very important”. Family 1, who tested their
child, and family 4, who did not test their child ranked it as “not important”. Families 2
and 5 ranked this item as “very important”. Family 2 tested their child while family 5 is
committed to it. Interestingly, these families ranked the “pro”: my child could do
something to lower his/her cancer risk as “very important”. These responses appear to be
contradictory.
Other Comments
Respondents were given several opportunities throughout the questionnaire to
provide qualitative responses. These comments were especially revealing. While some
responses reinforced the themes which have presented themselves in the quantitative data,
others introduced new issues which would be interesting to address in future studies.
Family 1 indicated that “info is power”. This family tested their children for p53
genetic mutations. The respondent had two daughters, who both passed away from cancerrelated issues. Additionally, the respondent has a diagnosis of a terminal cancer. This
family has quite a significant history of cancer diagnoses and subsequent deaths. It is
possible that this individual feels that knowing whether his children had the cancer
susceptibility gave him some kind of control, although both his children presumably had
p53 mutations. Power can be translated in a number of ways. While power can mean that
knowing genetic results may benefit the child’s health management, it may also mean that
it can allow the family to plan for the future, make lifestyle choices, etc.
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Respondent 3 provided the following statement:
“ I have not had my children tested because their father’s
opinion/request was not having them tested. He felt that being
aware of the risks and having regular checkups would be a better
option. He feared that if they were tested positive, it could have
adverse affects. I.E. ability to get health or life insurance,
psychological since their father lost his battle with cancer, etc. As
young adults I need to educate them with their options and allow

This response highlighted several key issues. This is a co-parent whose spouse had
passed away from cancer-related issues. First, this individual is respecting her partner’s
wishes. It is clear that the couple had put a lot of thought into this topic before the father
passed away, and that they had made a choice together to defer testing until the children
had reached adulthood. The couple appeared to be concerned about several issues.
Insurance discrimination is a theme which continues to present itself both here and in other
studies related to pre-symptomatic testing for cancer susceptibility (Patenaude et al., 1996).
The couple also feared that watching a parent with LFS die from cancer would cause the
children more anxiety when going through genetic testing themselves. It appears that this
individual is very knowledgeable about LFS and associated risks. She is making it her
responsibility to be vigilant about the health of her children and to share information and
help facilitate decision making when the children get older.
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Respondent 4 provided comments:

“I want to know as a parent. My kids already know they are at a greater risk
because of being related to my wife’s family. I do not want them to know
results until all 3 are ready as adults.”
“I do not want my kids to know results or even what the test is looking for until all
3 are adults or if one develops cancer. If one finds out, the others will worry.”
“I don’t want my kids to know results or even the real reason for the test other
than testing them is for research. Would prefer if draw is made by family doctor
as “routine” blood work. I do want to know and I also want my family doctor to
know (verbally).”

In previous sections, this individual indicated that he was in favor of predictive p53
genetic testing in children. However, he was strongly against involving children in the
decision making process and disclosing results to them. These qualitative comments are
consistent with the quantitative responses. This individual appears to believe that testing
would benefit the health of the child in some way but feels the need to play the role of
gatekeeper with this information. The children of this individual are ages 15, 16 and 20.
This individual’s responses are especially interesting considering the ages of his children,
one of which is considered to be past the age of majority, and is legally able to request
his/her own testing without parental permission. The other children may be considered to
be at the age of “assent”. It would likely be difficult to find a physician or genetic
counselor willing to test children of these ages without their assent.
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The issue of genetic testing in minors is becoming increasingly prevalent. One key
component is the concept of “assent”. For minors in healthcare, assent refers to the minor
understanding and agreeing to the proposed procedure or test (De Lourdes, Larcher &
Kurz, 2003).
In his comments, respondent 4 appears to have concerns about insurance
discrimination. He reports that he would want his childrens’ doctor to know test results
“verbally”. This individual presumably does not want genetic results to be documented in
their child’s medical record, which health insurance companies or other potentially
discriminating persons could access. Once again, fear of insurance discrimination appears
to color individuals’ view of pre-symptomatic testing.
Respondent 5 was a co-parent to an individual who had recently
passed away from cancer-related issues. The couple had one living daughter,
age 15, and a son who died at age 6 from cancer related causes. In e-mail
correspondence, respondent 5 included the following information:
“We have recently been discussing with (child) about getting her tested for
(LFS)”.
“We are living with the effects that losing a mother and a brother because
of (LFS), has on a child. The worries and fears that are created when she is ill
or just doesn’t feel good. (Child) is constantly worried about developing

Throughout the questionnaire, this respondent appeared to be strongly
in favor of pediatric testing. His P-TAS score was 55, which is the maximum
value. During the stage of change questionnaire, the individual was still in the
pre-contemplation stage, but reported that he was committed to obtaining p53
genetic testing for his daughter and disclosing the results.
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This individual brought up an interesting point that many parents most
likely consider. His 15-year old daughter could potentially have up to a 20%
risk of cancer before she turns 18. She has seen her younger brother and
mother suffer from their cancer diagnoses and eventually pass away. This
child may be experiencing excessive cancer-related anxiety by not knowing
whether she has the same cancer risks as her mother and brother. If she did
not inherit the p53 mutation from her mother, then this child has the general
population cancer risk. The estimated cancer for a female of the general
population to develop cancer before the age of 20 is 0.32% (Ries, Kosary,
Hankey, Miller, Clegg & Edwards, 1998). Alternatively, if she did inherit the
p53 mutation, the complaints and health concerns of this child may be taken
more seriously.

Strengths of Study
As no research has examined parental attitudes towards testing
children for p53 mutations, this is a pilot study. Other studies have looked at
parental feelings and beliefs regarding pre-symptomatically testing children
for other cancer predisposition syndromes such as Familial Adenomatous
Polyposis (FAP), Von-Hippel Lindau disease (VHL) and Hereditary Breast
and Ovarian Cancer syndrome (HBOC) (Andrews et al.,2006) (Peshkin et al.,
2009) (Rasmussen et al., 2010). Patenaude et al. (1996) questioned parents
about their attitudes regarding testing children for a theoretical cancer
predisposition gene. One of the largest strengths of this study is that it is the
first to focus specifically on parents whose children are at risk of inheriting
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p53 mutation and to ascertain parental attitudes toward testing children for
p53 genetic mutations.
Another strength of this study is its use of several validated measures
in pediatric genetic testing and health-related behavior (Tercyak et al.,
2002),(Andrews et al., 2006),(Peshkin et al., 2009), (Peterson et al.,2009).
The pediatric testing attitudes scale (P-TAS) has recently been validated and
is expected to play an integral role in future studies looking at parental
attitudes towards testing minors for cancer susceptibility (Peshkin et al.,
2009). The communication questionnaire has been used in several studies and
is shown to be reliable (Terycak et al., 2002, Terycak et al., 2006). The transtheoretical model has also been extensively used in health related research
and is a measure that is believed to accurately measure stage of change and
decisional balance (Prochaska & Velicer, 1997). Additionally, individuals
were given the opportunity to provide qualitative responses. We were
therefore able to collect both qualitative and quantitative responses from most
respondents. The tools used were appropriate for the study.

Limitations of Study
The major limitation to the study is our small sample size. Only 6 out of 25
potentially reachable participants returned the questionnaire, giving a response rate of
28.57%. We are unable to draw explicit conclusions about our population given this small
response rate. In this study, non-response may be attributed to a number of factors. A
previous study using the same population of participants showed a response rate of near
70% (Peterson et al., 2008). Surveys were conducted over the telephone, while ours were
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mailed-out. Past studies have shown that mail-out surveys were more revealing than
telephone, yet showed a lower response rate (Morrissey, 1995) (Erhart, Wetzel, Krugel &
Ravens-Sieberer, 2009). Although telephone reminder calls are believed to strengthen
response rate (Traina, MacLean, Park & Kahn, 2005), our attempt to do so did not appear
to be successful. Due to time constraints, we were not able to conduct the survey over the
telephone. If we had used the telephone to conduct the survey, it may have been possible to
probe participants for more qualitative responses, as those appeared to be the most
revealing in our study.
Low response rate may also be attributed to the timing of the initial survey
distribution. Our survey was initially mailed in mid-December, near the winter holidays.
Two reminder surveys were then mailed out. It is possible that the timing of initial survey
distribution contributed to the poor response rate. We are therefore unable to generalize our
results towards a greater population.
Another potential limitation of the study is that parental attitudes towards testing
children for cancer predisposition likely have many more factors which we did not inquire
about. Such factors may be child’s current and past health, health of parent(s) and siblings,
child’s maturity level and cognitive ability of the child. These are all factors which could
potentially play a large role in a parent’s decision whether to test their child for a p53
mutation.
Conclusion
Although clinical genetic testing has been available for Li-Fraumeni
syndrome, little is known about parental attitudes towards testing children for
p53 mutations. This is the first study to address this issue. In general, parents
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seem to be in favor of childrens’ rights to be tested for p53 mutations.
Although most people appear to agree that children should have the
opportunity to be tested, they vary in regard to their attitudes towards who
should be involved in the decision making process and when it should occur.
While some individuals believe that children should be tested as soon as
possible, others reported that it should occur later in adolescence or when the
child reaches the age of majority. Parents also varied in communication with
their children. Some reported having open discussions about genetic testing
and general health frequently, while others have reportedly never had these
conversations.
Using the health psychology trans-theoretical model, we ascertained
the decisional balance and stage of change of each individual. Decisional
balance appeared to be a reliable predictor of stage of change. Individuals
who favored the “pros” in decisional balance are either committed to test their
children for p53 genetic mutations or have already done it. Individuals who
ranked the “pros” and “cons” more equally appear to be in pre-contemplation
stage of testing their children.
Perhaps most revealing were the qualitative comments that the
participants provided us. These thoughtful responses highlighted several key
issues in considerations for pediatric genetic testing including concerns about
insurance discrimination and pediatric assent to genetic testing.
Although our small sample size does not allow us to draw any
conclusions about our population, individuals provided us with enlightening
responses. Li-Fraumeni syndrome is clearly a life-altering diagnosis. Parents
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considering whether to test their at-risk children for this devastating condition
do not appear to be taking the decision lightly. There is no straightforward
answer as to whether children should undergo p53 genetic testing. This and
future studies addressing this issue may improve communication between
health care providers and parents about pediatric genetic testing for cancer
predisposition syndromes.

Future Studies
As we limited our study to individuals who have children 27 years of
age or younger, it may be beneficial to expand the study population to all
individuals who have a diagnosis of or are at risk of inheriting Li-Fraumeni
Syndrome. This would likely improve the sample size. Additionally,
performing a telephone survey would most likely improve the survey
response and sample size. A telephone survey would also allow us to ask
probing questions and obtain more qualitative responses.
It would be interesting to see how the recently enacted genetic
information non-discrimination act (GINA) and health care reform will
change the concerns individuals have regarding insurance discrimination.
Literature often cites this to be a major deterrent to genetic testing (Patenaude
et al., 1996), (Veach, Bartels & LeRoy, 2001), (Hall, McEwen & Barton,
2005). Responses from this study are consistent with those reports. With
changing regulations on insurance discrimination and an evolving health care
model, individuals may alter their ideas about this possibility.
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Finally, it might be worthwhile to perform a similar study on
providers who may encounter issues such as pre-symptomatic p53 genetic
testing. This could be done by identifying providers who care for patients
who have a family history of Li-Fraumeni syndrome and providing them with
a similar survey as the one in our study. Comparisons could then be made
between responses of parents and provider. Results from this study could
provide insight on differing perceptions between parent and medical
specialist.
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Appendix A : Letter of Invitation

Department of Genetics-Unit 209
Phone: (713) 792-7555 Fax: (713) 794-4421
<Date>

<Name>
<Address Line 1>
<Address Line 2>

Dear Ms/Mr. <Name>:
I am writing to thank you for your continued participation in our research involving
Li Fraumeni
Syndrome (LFS), and to let you know about a new research opportunity. I would like to
invite you to take part in a research study entitled Attitudes of families with Li-Fraumeni
Syndrome, a rare hereditary cancer predisposition syndrome towards predictive testing in
children. We are interested in obtaining information about parental attitudes toward p53
genetic testing in their children.
We are inviting you because you have participated in our LFS research at M. D.
Anderson Cancer Center (MDACC). The study will include individuals with a diagnosis or
those who have family members with a diagnosis of Li-Fraumeni Syndrome. Your
decision to join this research study is voluntary. You may decline to participate, or choose
to discontinue participation at any time. Your decision about participation in this study or
answering questions will not change the care or services that you receive from MDACC.
Participation in this research study involves completing the enclosed survey
regarding your feelings toward p53 testing in your child. You or somebody in your family
has been diagnosed with Li-Fraumeni Syndrome, a cancer predisposition condition. As you
know, LFS is a rare hereditary condition that increases cancer risk, and is most often
attributed to genetic changes in the p53 tumor suppressor gene. We have identified a
mutation, or change in the p53 gene in you or a family member. As you may know, p53
testing is not routinely performed in minors for a variety of reasons. We are interested in
learning how you feel about having your child tested for the p53 mutation. The questions
that you will be answering will help the researchers and physicians to better understand the
needs of families with children at risk for LFS and provide the appropriate services. We
will ask you questions about how you feel about genetic testing in your children.
If you agree to participate in this study, please complete the questionnaire that is
included in this packet and return to us in the pre-addressed envelope. By consenting to
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this study, you will give us access to this questionnaire, as well as your MDACC medical
records.

If you choose to participate in the study, you will be asked to give your
identification number on the questionnaire. Your identification is: (Kindred number and
Unique number). This number allows us to determine who has responded to the study.
This questionnaire is also available online. If you prefer to do online survey, please
notify us at 713-745-3477 and we will send you the instructions. The online survey
consists of the same questions as the one that is included in this packet and was created
using a professional account on Survey Monkey, which is a confidential survey making
tool. Your response will be maintained strictly confidential and will only be shared with
study staff.
Although your participation in this project may not have direct benefit to you, it
will provide useful information that may advance our understanding of genetic testing.
Some of the questions on the survey may make you feel uncomfortable. You may decline
to answer any questions or stop taking the survey at any time. If you decide to participate
in the study, it is very important that you answer as honestly as you can to the questions
that are asked. Please complete this survey alone.
If you have any questions or would like more information, please contact Leslie
Newman at 713-745-3477 or Dr. Strong, MD at (713) 792-7555.
Thank you very much for considering this invitation to participate in our study.

Sincerely,

Leslie Newman, BS

Louise C. Strong, M.D

Graduate School of Biomedical Sciences
Chair
Email: leslie.a.newman@uth.tmc.edu
Genetics

Sue and Radcliffe Killam
Professor of Cancer
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APPENDIX B: Questionnaire

Instructions: We are interested in learning about your attitudes toward p53 testing for healthy children under the age of 21. As you may
know, p53 genetic testing for cancer susceptibility has not been routine in healthy minor age children due to several medical, social, and
psychological reasons, however p53 alterations do affect cancer risk in children, and we wish to learn about your experience and
attitudes toward such testing. The following questions are directed toward your personal feelings about genetic testing in healthy
minors.
Please indicate your agreement with each of the following statements using the scale below.
Strongl
y
Disagr
ee

Disagr
ee

Neithe
r
Agree
nor
Disagr
ee

Agree

Strongl
y
Agree

1. Children under age 18 should be given the opportunity to be tested
for the p53 mutation

1

2

3

4

5

2. Parents should decide if their children are allowed to have a p53
test or not, even if a doctor disagrees

1

2

3

4

5

3. Even though some of the cancers associated with p53 mutations do
not affect children until they reach adulthood, children should still be
offered p53 testing

1

2

3

4

5

4. Children should be involved in making the decision about whether
or not they participate in p53 testing

1

2

3

4

5

5. If children are tested and they carry a p53 mutation (that is, they
test positive), they should be told about their test result immediately

1

2

3

4

5

6. Even if there is no known prevention, treatment, or cure for the
cancers associated with p53 mutations, children should be offered p53
testing

1

2

3

4

5

7. If children are tested and they turn out to carry a p53 mutation (that
is, they test positive), then this information should be shared with the
child’s pediatrician

1

2

3

4

5

8. I want my child to be tested for a p53 mutation before age 18

1

2

3

4

5

9. If children are tested and they do not carry a p53 mutation (that is,
they test negative), they should be told about their test result
immediately

1

2

3

4

5

10. The benefits of children participating in p53 genetic testing
outweigh the risks

1

2

3

4

5

11. I am in favor of p53 gene testing for children

1

2

3

4

5

CONTINUED ON NEXT PAGE…
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I am in favor of p53 gene testing for my child if: (Circle One)
Yes

No

Unsure

12

My child has developed cancer

1

2

3

11

One of my other children has developed
cancer

1

2

3

12

He/She agrees to have testing

1

2

3

13

He/She requests testing

1

2

3

14

He/She is older than ten

1

2

3

15

If the results would help manage my child’s
health

1

2

3

17

16

At what age do you feel it is appropriate to test an individual
for a p53 mutation?

If results would help other family members

1

2

3
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Please complete the following for each of your biological children.

1

Child’s year of birth

2

Is this child
living?

3

If No, at what age did the child pass away?

Age:
Yes

No
Cause of death:

4

Gender
Male

5

Have you shared your family’s genetic testing results with this child?

Female

Yes

No

Not Applicable

The following questions pertain to conversations you may or may not have had with your child about
their risk of inheriting an alteration in the cancer susceptibility gene, p53, and genetic counseling and
testing.
How often have you:

How comfortable were you with
this?
Not at

SomeRarely

all

Mostl
y

Very

at all

A
little
bit

Not
Often

times

6

Talked with this child about
genetic counseling and testing
for p53?

1

2

3

4

1

2

3

4

7

Asked this child how he/she
felt about genetic testing?

1

2

3

4

1

2

3

4

8

Tried to reassure this child that
you would be OK?

1

2

3

4

1

2

3

4

9

Tried to reassure this child that
he/she would be OK?

1

2

3

4

1

2

3

4
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CONTINUED ON NEXT PAGE…

Please indicate the steps you have (or have not) taken regarding seeking genetic testing
for your child.
I have
no
interest
in this

I
haven’t
thought
about it

I have
thought
about it

I am
committed
to it

I’ve
already
done it

10

Discussed genetic testing with
this child

1

2

3

4

5

11

Sought information regarding
testing for a p53 mutation in
this child

1

2

3

4

5

12

Made an appointment with a
doctor/genetic counselor

1

2

3

4

5

13

Met with a doctor/genetic
counselor

1

2

3

4

5

14

Had this child tested for a p53
mutation

1

2

3

4

5

15

Shared this child’s genetic
testing results with him or her

1

2

3

4

5

CONTINUED ON NEXT PAGE…
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THE FOLLOWING QUESTIONS (15-19) ARE FOR INDIVIDUALS WHOSE CHILD HAS HAD
GENETIC TESTING.
If this child has not had genetic testing, please SKIP TO # 20.
Please indicate how important you feel each of the following was in your decision to pursue
genetic testing in this child using the 1-5 point scale. The following list includes reasons some
people give for wanting to have genetic testing.
Not
Slightly Somewhat
Very
Important
Important Important Important
Important

18

I would have been relieved to
know that my child did not
have a p53 mutation
My family’s experience with
cancer made me more
concerned about my child’s
own risk for the disease
My child could do something
to lower his/her cancer risk

19

I / My child could plan for the
future

16

17

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

Other (please write)
20

THE FOLLOWING QUESTIONS (20-24) ARE FOR INDIVIDUALS WHOSE CHILD HAS NOT
HAD GENETIC TESTING.
If your child has had genetic testing, this portion of the survey is complete. If you have other children
whom you have not completed the survey for, please do so in the provided forms. If you have completed
the questionnaire for all of your children, please turn to the last page.

Please indicate how important you feel each of the following would be to you using the 1-5 point
scale. The following list includes reasons some people give for wanting to have genetic testing.
Not
Slightly Somewhat
Very
Important
Important Important Important
Important

21

22

23

I would be relieved to know
that my child did not have a
p53 mutation
My family’s experience with
cancer makes me more
concerned about my child’s
own risk for the disease
My child can do something
to lower his/her cancer risk

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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24

I / My child can plan for the
future

25

Other (please write)

1

2

3

4

5

The following list includes reasons some people give for NOT wanting to have genetic testing.
Please indicate how important you feel each of the following would be for you using the same 15 point scale.
Not
Slightly Somewhat
Very
Important
Important Important Important
Important
26
27
28
29
30
31
32

I’m afraid I would get too upset
I’m afraid my child would get
too upset
I am concerned that having the
test might cause problems with
my child’s insurance
There is nothing my child can do
about getting cancer
I am concerned about my
family’s reaction
I am worried about how it would
affect my child’s future

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

Other (please write)

Thank you for completing this section of the survey. If you have other children whom you have not
completed the survey for, please do so in the provided forms. If you have completed the questionnaire for all
of your children, please turn to the last page.
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The following are questions about YOU. Please complete the following sections.
1

Gender

Male

2

What is your
marital
status?

What is the highest grade or level of
schooling you completed?

Female
Single
Married
Separated
Divorced
Widowed

4

3

What is your current
occupational status?

5

Some high school
High school graduate
Some college
College graduate (4 Year Degree)
Associate’s degree

Upper-level degree (Masters, PhD, MD)
What is your (combined) annual household income?

Employed (Full Time)
Employed (Part Time)
Less than $25,000
Unemployed (Not
seeking a job)
Unemployed (Seeking a

$25,000 - $50,000
$50,000 - $75,000

job)
More than $75,000
Homemaker
Student
Retired

Thank you very much for completing this questionnaire. The information you have provided has been very
helpful and we appreciate your thoughtful answers.
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Appendix C - Reminder Letter to Non-Responders

Date
Name
Address
Dear
Over the last several weeks we have tried to contact you at the above address about our
study Attitudes of families with Li-Fraumeni Syndrome, a rare hereditary cancer
predisposition syndrome towards predictive testing in children. As of <the date shown at
the top of this letter>, we have we have not received the questionnaire back from you nor
have we received a refusal to take part in this study.
We are interested in obtaining information about parental attitudes toward p53 genetic
testing in their children. The questions that you will be answering will help the researchers
and physicians to better understand the needs of families with children at risk for LFS and
provide the appropriate services. Participation in the study involves signing an informed
consent and completing a questionnaire.
If you are interested in taking part in this study and have lost the informed consent and
questionnaire, we have enclosed another copy for your convenience. If you do not wish to
take part in this part of the study, please indicate this and also return the blank
questionnaire to us in the pre-addressed envelope.
We appreciate your participation in the study. If you have any questions, please contact
me at your earliest convenience at 713-745-3477 or Dr. Louise Strong at (713) 792-7555.
Sincerely,
Leslie Newman, BS
U.T. M.D. Anderson Cancer Center
1515 Holcombe Blvd., Box 209
Houston, Texas 77030-4009
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